Antonio
Pineda Lucena
Investigador Senior
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (9)
2023
-
Photodynamic nasal SARS-CoV-2 decolonization shortens infectivity and influences specific T-Cell responses
Frontiers in Cellular and Infection Microbiology, Vol. 13
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
2022
-
CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage
Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1314-1325
-
Impact of CYLD on chromatin structure and histone methylation in malignant melanoma
International Journal of Molecular Medicine, Vol. 49, Núm. 5
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Trimethylamine N-oxide (TMAO) drives insulin resistance and cognitive deficiencies in a senescence accelerated mouse model
Mechanisms of Ageing and Development, Vol. 204
2021
-
Metabolic footprint of aging and obesity in red blood cells
Aging, Vol. 13, Núm. 4, pp. 4850-4880
2020
-
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis
Journal of medicinal chemistry, Vol. 63, Núm. 17, pp. 9237-9257
2018
-
Metabolic fingerprint of insulin resistance in human polymorphonuclear leucocytes
PLoS ONE, Vol. 13, Núm. 7